Description
RWJ-67657 is a potent, orally active inhibitor of p38 mitogen-activated protein kinase. It selectively inhibits p38α and p38β over p38γ, p38δ and a range of other kinases. RWJ-67657 inhibits the release of TNF-α by lipopolysaccharide (a monocyte stimulus)-treated human peripheral blood mononuclear cells with an IC50 of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (a T cell stimulus), with an IC50 of 13 nM. RWJ-67657 may have use as a treatment for inflammatory diseases.
Alias
RP1-179N16.5, CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2, PRKM14, PRKM15, RK, SAPK2A, p38, P38alpha
Product Overview
Inhibitor of p38 mitogen-activated protein kinase
Stability
2 years -20 centigrade Powder
1 month -4 centigrade in DMSO
More than one month -80 centigrade in DMSO
Synonyms
RP1-179N16.5, CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2, PRKM14, PRKM15, RK, SAPK2A, p38, P38alpha
Molecular Formula
C27H24FN3O
Chemical Name
4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol
Solubility
DMSO > 112mg/mL Water >1mg/mL Ethanol > 4mg/mL
Download Datasheet